abrdn plc bought a new stake in Personalis, Inc. (NASDAQ:PSNL - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 297,889 shares of the company's stock, valued at approximately $1,722,000. abrdn plc owned about 0.42% of Personalis at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also bought and sold shares of the company. nVerses Capital LLC bought a new stake in Personalis in the 3rd quarter valued at $40,000. SG Americas Securities LLC bought a new stake in Personalis in the 4th quarter valued at $63,000. IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its holdings in Personalis by 42.5% in the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 15,103 shares of the company's stock valued at $81,000 after purchasing an additional 4,504 shares during the period. China Universal Asset Management Co. Ltd. bought a new stake in Personalis in the 4th quarter valued at $87,000. Finally, International Assets Investment Management LLC boosted its holdings in Personalis by 438.0% in the 3rd quarter. International Assets Investment Management LLC now owns 20,982 shares of the company's stock valued at $113,000 after purchasing an additional 17,082 shares during the period. 61.91% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
PSNL has been the subject of a number of research reports. HC Wainwright reduced their price target on shares of Personalis from $11.00 to $8.00 and set a "buy" rating for the company in a report on Monday, January 27th. Lake Street Capital increased their price target on shares of Personalis from $7.00 to $9.00 and gave the company a "buy" rating in a report on Wednesday, January 8th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $7.25 price objective on shares of Personalis in a report on Wednesday, January 8th.
Check Out Our Latest Research Report on PSNL
Personalis Stock Performance
Shares of NASDAQ:PSNL traded up $0.52 during midday trading on Friday, reaching $5.51. 2,444,710 shares of the company's stock were exchanged, compared to its average volume of 1,118,292. The company's 50 day simple moving average is $5.23 and its two-hundred day simple moving average is $4.93. The firm has a market capitalization of $389.28 million, a PE ratio of -3.28 and a beta of 1.73. Personalis, Inc. has a 12 month low of $1.13 and a 12 month high of $7.20.
Personalis Company Profile
(
Free Report)
Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.
See Also
Before you consider Personalis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Personalis wasn't on the list.
While Personalis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
